INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Inclusion Criteria:

• Adults ≥ 18 years at Visit 1

• Subjects must be contractually capable and mentally able to understand and followthe instructions of the study personnel

• Physician's diagnosis of chronic fibrosing Interstitial lung disease (ILD) with aprogressive phenotype, except Idiopathic pulmonary fibrosis (IPF)

• Initiation of nintedanib as first antifibrotic therapy according to physician´sdecision which has been made as part of routine care prior to and independent ofstudy inclusion

• Outpatients not currently hospitalized with a life expectancy > 12 months perinvestigator's assessment

• Written informed consent prior to study participation

• Current Forced vital capacity (FVC) measurement (taken within the last 3 months)available in the patient file

• Women of childbearing potential must take appropriate precautions against gettingpregnant during the intake of nintedanib.

Exclusion Criteria:

• Patients with contraindications according to Summary of product characteristics (SmPC)

• Prior use of any antifibrotic treatment

• Lack of informed consent

• Pregnant or lactating females

• Any physician diagnosed exacerbation of Interstitial lung disease (ILD) in thepatient's history file, irrespective of time since event

• Current diagnosis of lung cancer

• Respiratory failure (pH < 7,35 and/ or respiratory rate > 30/min) in the patient'shistory

• Participation in a parallel interventional clinical trial

• Patients being spouse or lateral relatives to the second degree or economicallydependent from the investigator